drugset

drugset / Trial / NCT01321359

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis

NCT01321359 ↗

Phase 3 Completed 907 enrolled NanoBio Corporation

RandomizedParallel-groupDouble-blindTreatment

Summary

Demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).

Timeline

Start: 2011-04
Primary completion: 2012-01
Completion: 2012-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	NB-001	Other / unclassified	0.3 %	Topical

Indications